Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study [Corrigendum]

Abstract

Strange C, Tkacz J, Schinkel J, et al. Int J Chron Obstruct Pulmon Dis. 2023;18:2245–2256. The authors have advised that there are errors in the 95% CI interval values on page 2248. Results, Baseline and Follow-Up Exacerbation Rates, sentence 3, the text “Relative rates of total exacerbations for prompt were 0.76, 95% CI: (0.72 – 0.79) and 0.66, 95% CI: (0.63 – 0.69) versus delayed and very delayed” should read “Relative rates of total exacerbations for prompt were 0.76, 95% CI: (0.69 – 0.83) and 0.66, 95% CI: (0.60 – 0.72) versus delayed and very delayed”. Results, Baseline and Follow-Up Exacerbation Rates, sentence 5, the text “Relative rates of severe exacerbations for prompt were 0.75 (95% CI: 0.67-0.90) and 0.38 (95% CI: 0.29-0.47) versus delayed and very delayed” should read “Relative rates of severe exacerbations for prompt were 0.75 (95% CI: 0.45-1.15) and 0.38 (95% CI: 0.22-0.55) versus delayed and very delayed”. The authors apologize for these errors and confirm that the overarching interpretation of the results and conclusions of the study remain consistent with the originally published article and no other text or figures are affected.

Keywords

• copd
• triple therapy
• exacerbations
• delayed therapy
• budesonide/glycopyrrolate/ formoterol fumarate